vendredi 19 juillet 2013

Press Review (July 20, 2013) – Revue de presse (20 juillet 2013)

New surgical knife can instantly detect cancer
A knife can help surgeons make sure they removed all the cancerous tissue, doctors say.
By Maria Cheng. In USA Today

Big Government Opens Big Database For Cancer ResearchSt.
For those of us without degrees in molecular biology, the idea of “personalized medicine” – or PM – can often seem like a vague and distant concept. In this case, the Wikipedia definition of PM is pretty good:
“Personalized medicine or PM is a medical model that proposes the customization of healthcare – with medical decisions, practices, and/or products being tailored to the individual patient. The use of genetic information has played a major role in certain aspects of personalized medicine, and the term was even first coined in the context of genetics (though it has since broadened to encompass all sorts of personalization measures). To distinguish from the sense in which medicine has always been inherently “personal” to each patient, PM commonly denotes the use of some kind of technology or discovery enabling a level of personalization not previously feasible or practical.”
By Dan Munro. In Forbes                                  

Colorectal Cancer Survivors May Face Risk Of Second Cancer
Researchers from the University of Washington and Fred Hutchinson Cancer Research Center found that colorectal cancer survivors have a 15 percent increased risk of a second cancer.
By Amanda Chan. In Huffington Post               

Finding Cancer Cells in the Blood
Technologies that can pull tumor cells from patients’ blood are giving researchers an unprecedented look at cancer.
By Susan Young. In MIT Technology Review   

Deaths Force End to Celgene Trial to Expand Top Cancer Drug (1)
Celgene Corp. (CELG:US) stopped a trial of Revlimid (lenalidomide), its biggest-selling drug, after more people died using the product than those who were given a competing therapy.
By Drew Armstrong. In BusinessWeek

Cancer : un scalpel "intelligent" qui détecte les tissus atteints
Au cours des premiers tests effectués, ce "e-scalpel" a détecté avec un taux de réussite de 100% les échantillons provenant de 91 patients.

Cancers en France : davantage de cas mais une mortalité en baisse
Le nombre de cas de cancers en France augmente depuis 1980. Mais la mortalité, elle, recule. Malgré tous les progrès, 2012 est restée très meurtrière, puisque 148.000 hommes et femmes sont décédés des suites de leur tumeur
Dans Futura Sciences

Aucun commentaire:

Enregistrer un commentaire